Selective CDK4/6 Inhibitors for Cancer Stem Cell Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer stem cells (CSCs) are resistant to conventional cancer therapies, leading to treatment failure and poor clinical outcomes due to their ability to survive harsh conditions and form 3D spheroids, which are responsible for tumor recurrence and metastasis.
Innovation Solution
Development of substituted pyridinylpiperazine-pyrrolopyrimidine compounds that act as potent CDK 4/6 inhibitors to target and eliminate CSCs, preventing anchorage-independent growth and reducing cancer resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (chemotherapy and radiation) are used, then treatment of bulk cancer cells is achieved, but cancer stem cells survive and cause tumor recurrence and metastasis
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy/radiation to CDK4/6 inhibition, targeting a specific molecular pathway (cyclin D-CDK4/6-retinoblastoma protein axis) that is critical for cancer stem cell proliferation. This parameter change enables selective targeting of CSCs while sparing normal cells, resolving the resistance issue
Solution Approach 2:
The patent introduces CDK4/6 inhibitors as intermediary molecules that mediate between the therapeutic goal (CSC elimination) and the molecular mechanism (cell cycle control). These inhibitors act as mediators by blocking the interaction between cyclin D and CDK4/6, thereby preventing retinoblastoma protein phosphorylation and inducing cell cycle arrest in CSCs
2Reliability
If cancer stem cells are targeted to prevent recurrence and metastasis, then treatment reliability improves, but new therapeutic compounds are required beyond conventional therapies
Solution Approach 1:
The patent segments the cancer cell population by identifying and targeting cancer stem cells specifically through CDK4/6 inhibition, rather than treating all cancer cells uniformly. This segmentation allows for precise targeting of the small subset of CSCs responsible for recurrence and metastasis, improving prevention reliability
Solution Approach 2:
The patent changes the chemical parameter space by developing novel substituted pyridinylpiperazine-pyrrolopyrimidine compounds with specific molecular structures optimized for CDK4/6 binding. These structural parameters (substituents, ring systems, molecular weight) are carefully tuned to achieve selective inhibition while maintaining drug-like properties for manufacturability
3Reliability
If CDK4/6 inhibitors are used to target cancer stem cells, then anchorage-independent growth is prevented, but selective inhibition of CDK 4/6 without affecting other CDKs is required
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (pyridinylpiperazine-pyrrolopyrimidine core structure with particular substituents) that create localized interactions with CDK4/6 binding pockets. These local structural qualities enable selective binding to CDK4/6 while avoiding off-target effects on other cyclin-dependent kinases, achieving the required manufacturing precision for selective inhibition
Data Source
AI summary
This disclosure describes embodiments of selective and potent CDK 4/6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. As described herein, compounds of the present approach comprise substituted pyridinylpiperazine-pyrrolopyrimidine compounds having a fatty acid moiety. The compounds described herein may be used as pharmaceutical compounds for anti-cancer therapies, and are useful for the treatment, prevention and/or amelioration of cancer. Formula (a)